Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD/MAD Study of Apimostinel in Healthy Volunteers
NCT05597241Phase 1Completed
- Start
- Oct 2022
- Primary completion
- Apr 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of apimostinel in major depressive disorder (MDD) (10 cohorts). Primary endpoint: Treatment Emergent Adverse Events at 36 days. Started Oct 2022; status: completed.
02
Drugs
apimostinel
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05597241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05597241.